Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $26.6 million.

  • Heron Therapeutics' Net Cash Flow rose 26100.61% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 29003.07%. This contributed to the annual value of -$2.9 million for FY2024, which is 12159.54% down from last year.
  • As of Q3 2025, Heron Therapeutics' Net Cash Flow stood at $26.6 million, which was up 26100.61% from -$2.8 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Net Cash Flow registered a high of $131.4 million during Q2 2021, and its lowest value of -$69.0 million during Q4 2021.
  • In the last 5 years, Heron Therapeutics' Net Cash Flow had a median value of -$6.2 million in 2023 and averaged -$3.3 million.
  • Per our database at Business Quant, Heron Therapeutics' Net Cash Flow plummeted by 79049.71% in 2021 and then skyrocketed by 106987.42% in 2023.
  • Over the past 5 years, Heron Therapeutics' Net Cash Flow (Quarter) stood at -$69.0 million in 2021, then surged by 49.19% to -$35.1 million in 2022, then soared by 82.37% to -$6.2 million in 2023, then surged by 100.99% to $61000.0 in 2024, then soared by 43427.87% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, -$2.8 million for Q2 2025, and -$6.5 million during Q1 2025.